Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 8/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 7/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.39 |
| ▸ | JUN | P05412 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914272 | 0.94 | PRMT5 (0.44) | MAPK8MAPK9MAPK14KDRMAPK10 | |
| SCHEMBL5317262 | 0.80 | MAPK8 (0.39) | MAPK8MAPK9MAPK14KDRMAPK10 | |
| SCHEMBL3924389 | 0.80 | MAPK8 (0.40) | MAPK8MAPK9MAPK14KDRMAPK10 | |
| SCHEMBL5264929 | 0.75 | IRAK1 (0.41) | MAPK8MAPK9MAPK14MAPK10JUN | |
| SCHEMBL5913989 | 0.75 | AURKA (0.42) | MAPK8MAPK9MAPK14MAPK10JUN | |
| SCHEMBL5914429 | 0.74 | EPHB4 (0.42) | MAPK14KDRFGFR1EPHB4 | |
| SCHEMBL5914088 | 0.73 | USP30 (0.46) | MAPK14PRMT5 | |
| SCHEMBL5948116 | 0.73 | USP30 (0.44) | MAPK14PRMT5CNR1 | |
| SCHEMBL5914072 | 0.73 | SQOR (0.38) | KDRCNR1 | |
| SCHEMBL5914305 | 0.72 | MAPK14 (0.44) | MAPK8MAPK9MAPK14MAPK10JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | MAPK8 1760/4885MAPK9 2753/4885MAPK14 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.